Nuvectis Pharma, Inc. (NVCT) compared with its closest peers (GYRE, NGNE, MNPR, CTMX, ESPR). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Gyre Therapeutics, Neurogene, Monopar Therapeutics, CytomX Therapeutics, Esperion Therapeutics, Ironwood Pharmaceuticals, Zevra Therapeutics, Assembly Biosciences, Rigel Pharmaceuticals and Cryoport share Nuvectis Pharma's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $768.30M | 352.0 |
| Neurogene Inc. (NGNE) | $772.74M | -4.9 |
| Monopar Therapeutics Inc. (MNPR) | $725.08M | -35.4 |
| CytomX Therapeutics, Inc. (CTMX) | $714.71M | -28.5 |
| Esperion Therapeutics, Inc. (ESPR) | $821.21M | -33.7 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Zevra Therapeutics, Inc. (ZVRA) | $701.40M | 6.4 |
| Assembly Biosciences, Inc. (ASMB) | $700.00M | -62.0 |
| Rigel Pharmaceuticals, Inc. (RIGL) | $857.22M | 13.7 |
| Cryoport, Inc. (CYRX) | $866.86M | 6.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
NVCT overview · NVCT earnings · NVCT financials · NVCT KPIs · NVCT documents · NVCT ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.